Mental Health

FDA approves Uzedy, an extended-release injectable formulation of risperidone, enhancing treatment options for adults with bipolar I disorder.

Public debate intensifies as Robert F. Kennedy Jr compares selective serotonin reuptake inhibitors (SSRIs) to heroin, prompting mental health experts to clarify antidepressant use and withdrawal misconceptions.

Combining tramadol with CYP2D6-inhibiting antidepressants raises seizure risk in older adults, highlighting the need for careful medication management.

The authors wrote that patients with CKD under the age of 60 years may be at a greater risk of depression.

Recent studies reveal that simvastatin does not enhance escitalopram's effects in treating depression, despite improving metabolic health in obese patients.

Careful selection of pharmacotherapy and close monitoring are crucial to ensuring safety and efficacy.

Pharmacists are key to closing care gaps and supporting long-term recovery.

Pharmacists enhance patient safety by addressing common medication errors, ensuring proper drug use, and improving therapeutic outcomes in clinical practice.

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

MM120 shows promise in treating generalized anxiety disorder, demonstrating significant symptom relief and a potential shift in psychiatric treatment approaches.

FDA approves a new extended-release suspension formulation of risperidone for schizophrenia, expanding treatment options for patients.

Research reveals associations between body composition, fitness, and mental health in children, highlighting the impact of obesity on anxiety and depression.

Research shows that individuals who use cannabis to self-medicate, especially those with a history of childhood trauma, face heightened risks of paranoia and adverse mental health outcomes.

Individuals with bipolar disorder are at nearly a 2-fold higher risk of heart failure, which is marked as the main cause of premature cardiovascular mortality.

CT-155, an investigational prescription digital therapeutic, was found to improve motivation, sociality, and other negative symptoms in patients with schizophrenia as an adjunct to antipsychotic treatment.

NRX-100 receives FDA fast track designation, offering hope for treating suicidal ideation in depression and bipolar disorder, addressing a critical health crisis.

Pharmacists guide pregnant women in balancing depression treatment with SSRI safety, addressing risks of untreated depression and neonatal adaptation syndrome.

Joel Stanley of Ajna Biosciences reflects on the regulatory challenges surrounding MDMA-assisted therapy, outlines lessons for future psychedelic drug trials, and emphasizes the importance of scientific rigor, interdisciplinary infrastructure, and the evolving role of pharmacists in ensuring safe clinical integration.

In the double-blind portion of Vibrance-1, alixorexton improved wakefulness while eliciting broad benefits in patient-reported outcomes.

Unique barriers can lead to psychiatric medication adherence rates as low as 26%.

Statins such as simvastatin do not have additional antidepressive effects in combination with standard escitalopram treatment in patients with comorbid major depressive disorder (MDD) and obesity.

Lumatperone showed a 63% reduction in relapse risk for patients with schizophrenia, promising improved patient stability and care.

The authors wrote that a life course approach to the treatment and prevention of depression may help reduce individual burdens of dementia.

A multidisciplinary team enhances psychiatric care by empowering community pharmacists to administer long-acting injectable antipsychotics, improving patient adherence and outcomes.